<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4544">
  <stage>Registered</stage>
  <submitdate>13/10/2013</submitdate>
  <approvaldate>13/10/2013</approvaldate>
  <nctid>NCT01965223</nctid>
  <trial_identification>
    <studytitle>A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)</studytitle>
    <scientifictitle>Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial</scientifictitle>
    <utrn />
    <trialacronym>SAFRON II</trialacronym>
    <secondaryid>TROG 13.01</secondaryid>
    <secondaryid>TROG 13.01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer</healthcondition>
    <healthcondition>Metastases to the Lung</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - Multi-fraction SABR
Treatment: other - Single Fraction SABR

Experimental: Multi-fraction SABR - Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.

Experimental: Single fraction SABR - Radiotherapy: 28Gy delivered in 1 fraction


Treatment: other: Multi-fraction SABR
Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.

Treatment: other: Single Fraction SABR
Single fraction SABR; 28Gy delivered in 1 fraction

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Toxicity - The primary outcome is safety, defined as number of participants experiencing less than or equal to 5% toxicity at 12 months post treatment (toxicity as measured by CTCAE V4).</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life - To compare quality of life outcomes between techniques assessed using EQ-5DL and MDASI-LC questionnaires.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to local failure - Local progression free survival assesed by CT scan and clinical assessment</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival - Overall survival assesed by clinical assessment</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to distant failure - Time to distant failure assessed by CT scan and clinical assessment</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resources use and costs associated with treatment - Resources use and costs associated with treatment assessed by EQ5DL and accessing Medicare data</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Free Survival - Disease free survival will be measured from the date of randomisation to the date of a local recurrence, regional or distant metastasis, or death from any cause, whichever occurs first.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. A maximum of three metastases to the lung from any non-haematological malignancy

          2. Tumour diameter =5cm

          3. Targets are located away from central structures (defined as 2cm beyond bifurcation of
             lobar bronchi and central airways). Targets in proximity to chest wall and mediastinum
             that meet these inclusion criteria are eligible.

          4. Patients must be medically inoperable, technically high risk or have declined surgery.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previous high-dose thoracic radiotherapy.

          2. Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently
             with treatment. Hormonal manipulation agents are not excluded (e.g. aromatase
             inhibitors, selective oestrogen receptor modulators, and gonadotrophin releasing
             hormone receptor modulators)

          3. Targeted agents (such as sunitinib and tarceva) within 7 days of commencement of
             treatment, or concurrently with treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>84</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Cambelltown Hospital - Cambelltown</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Calvary Mater Hospital - Newcastle</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Northern Sydney Cancer Centre (RNS) - St Leonards</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Peter MacCallum Cancer Center - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2560 - Cambelltown</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3002 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Lung Cancer Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to determine the safety (defined as number of participants
      experiencing = 5% toxicity at 12 months post treatment) of stereotactic ablative fractionated
      radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01965223</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Shankar Siva</name>
      <address>Peter MacCallum Cancer Centre, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Shankar Siva</name>
      <address />
      <phone>+61 3 9656 1111</phone>
      <fax />
      <email>shankar.siva@petermac.org</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>